

Referências:

1. Ministério da Saúde. Secretaria de Atenção Especializada à Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos em Saúde. Portaria conjunta nº 17, de 01 de outubro de 2021. Protocolo Clínico e Diretrizes Terapêuticas da Retinopatia Diabética [internet]. 2021, Oct 01 [cited 2022, Jan 31]. Available from: https://www.gov.br/saude/pt-br/assuntos/protocolos-clinicos-e-diretrizes-terapeuticas-pcdt/arquivos/2021/portal-portaria-conjunta_pcdt_retinopatia-diabetica_.pdf
2. EYLIA: aflibercepte. Farm. Resp. Dra. Dirce Eiko Mimura. São Paulo: Bayer S.A. VE0119-CCDS12. Bula do paciente. Disponível em <https://www.eylia.com.br/sites/g/files/vrxlpx13736/files/2021-06/visualizar-bula-profissional.pdf>
3. Romero-Aroca P. Managing diabetic macular edema: the leading cause of diabetes blindness. *World J Diabetes*. 2011;2(6):98-104.
4. Tan GS, Cheung N, Simó R, et al. Diabetic macular oedema. *Lancet Diabetes Endocrinol*. 2017;5(2):143-55.
5. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. *JAMA*. 2007;298(8):902-16.
6. Corcóstegui B, Durán S, González-Albarrán MO, et al. Update on diagnosis and treatment of diabetic retinopathy: a consensus guideline of the working group of ocular health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society). *J Ophthalmol*. 2017;2017:8234186.
7. Wong TY, Cheung CMG, Larsen M, et al. Diabetic retinopathy. *Nat Rev Dis Primers*. 2016;2:16012.
8. Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. *Diabetes Care*. 2004;27 SUPPL 1:S84-7.
9. National Eye Institute. National Institutes of Health (NIH). Macular edema [internet]. [cited 2020 Aug 10]. Available from: <https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/macular-edema>
10. Varma R, Bressler NM, Doan QV, et al. Prevalence of and risk factors for diabetic macular edema in the United States. *JAMA Ophthalmol*. 2014;132(11):1334-40.